|
|
 |
Team |
 |
 |
S. Douglas Sheldon
Partner |
|
S. Douglas. Sheldon is a co-founder and Managing Partner of ESP Equity Partners, LLC , a private equity fund with offices in New Jersey, Miami , Beijing and Bangkok. Previously, in 2000, Mr. Sheldon co-founded ESP Partners LLC, the predecessor to ESP Pharma, a specialty pharmaceutical company acquired by PDL BioPharma in 2005. He has over 30 years of pharmaceutical and related healthcare experience, both internationally and domestically, including having served as Vice-President of Strategic Partnership Development at Parke-Davis Pharmaceuticals and earlier in his career as Vice-President Animal Health at Pfizer Asia Management Center ( Hong Kong). Doug began his career with Pfizer, Inc. where he served nearly 17 years in senior international finance, marketing, country management, and regional line management assignments in South America and Asia. He left Pfizer in 1991 to form TTMC, Ltd, a venture company focused on healthcare and life sciences businesses in South East Asia. Later, in 1994 he founded the Indochina Healthcare Ltd (IHL) joint venture operations in Thailand, Hong Kong, Vietnam and Myanmar, merging TTMC's hospital products business in orthopedics and urology with the oncology and cardiovascular business of Hospira Inc. (formerly Mayne Pharma). Today, he continues to actively serve as an Executive Director and Chairman of IHL. Mr. Sheldon also serves on the Board of Directors of EKR Therapuetics Inc and ESP Chinapharma (Beijing) , a specialty pharma company .
Mr. Sheldon, who is also fluent in Spanish, received his B.S. in Chemistry from LeMoyne College and M.B.A. in Finance and Marketing from Syracuse University.He served as an officer (Lieutenant Commander) in the U.S.Navy in both active duty (S.E. Asia) and the reserves.
|
 |
| Dr. Jeffery Z. Li Partner |
|
Dr. Jeffery Z. Li is a co-founder and general partner of ESP Equity Partners, LLC. Dr Li has more than 17 years of experience in the pharmaceutical industry spanning scientific research, business development, marketing and sales. Prior to co-founding ESP Equity, Dr. Li was a co-founder of ESP Partners LLC, then co-founder of ESP Pharma where he identified and facilitated the acquisition of Cardene IV, a key value driver for the company. ESP Pharma was acquired by Protein Biopharma (NASDAQ: PDLI) for more than $ 500 MM dollars in 2005. Prior to ESP Partners, Dr Li held several management positions with increasing responsibilities at Parke-Davis, the pharmaceutical division of Warner-Lambert (Now Pfizer). Prior to Warner-Lambert, Dr Li was a founding member of Enzyme Design, a biotech company. Dr. Li received his doctoral training from Harvard and published a number of peer-reviewed articles in leading scientific journals.
Dr. Li holds a Doctor of Science from Harvard, an MBA from the University of Michigan and a BS in Biology and a BS in Physics from Tsinghua University in Beijing, China.
|
 |
| Howard Weisman Partner |
|
Howard Weisman is a co-founder and general partner of ESP Equity Partners LLC . He is also former Chairman and Chief Executive Officer, EKR Therapeutics Inc. , a company he co-founded in Nov. 2005 . Formerly as co-founder, President, Chief Operating Officer and Director of ESP Pharma, a specialty pharmaceutical company, he led the company from initial angel financing up until its sale to Protein Design Labs (now PDL Biopharma) for $ 500 million in early 2005 . Mr.Weisman began his career at Merck & Co, Inc. and held several positions of increasing responsibility in hospital sales and marketing management for Merck's hospital product line. Mr. Weisman joined Parke-Davis in 1994 as Director of New Products and later was Senior Director, Diabetes Marketing where he oversaw the launch of Rezulin in 1997.
He went on to become the Senior Director of Strategic Partnership Development at Parke-Davis and co-founded the company E-Business Unit in 1999. Mr. Weisman holds a BA in Chemistry from Rutgers University and attended Princeton University Graduate School of Chemistry.
|
 |
Hiro Iwasaki
Venture Partner |
|
Mr. Hiro Iwasaki is a Venture Partner with ESP Equity Partners, LLC, a private equity fund with offices in New Jersey, Miami, Beijing and Bangkok. Iwasaki-san was formerly the CEO and President of Pfizer Japan, the largest pharmaceutical company in Japan from 2006 to 2010. He has more than 40 years of experience in the pharmaceutical industry spanning sales, marketing, business development and public affairs. He has worked in Pfizer's Asia Management Center as a Marketing Director (1982-1983) and was Country Manager of Hong Kong and Macau between 1975-1976. He is currently Executive Adviser and Honorable Chairman of Pfizer Japan.
Mr.Iwasaki has a BA in Economics from Keio University, an MA in International Economics from Indiana University, and an MBA from Cornell University. Mr.Iwasaki is based in Tokyo.
|
|
